AIA Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

AIA Group’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,000	Closed	-$290K	–	533
2022 Q1	$290K	Buy	+4,000	New	+$278K	0.01%	302

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

AIA Group's RARE Position: Q2 2022 in Review

AIA Group sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2022, closing a stake of 4,000 shares — an estimated $290K sold.

AIA Group first reported a position in RARE in Q1 2022 and held it in 1 quarter. The position peaked at $290K in Q1 2022. 223 funds tracked by Wall St. Rank hold RARE as of Q2 2022.

AIA Group reported no remaining Ultragenyx Pharmaceutical position as of Q2 2022 after selling out during the quarter.
AIA Group sold 4,000 Ultragenyx Pharmaceutical shares in Q2 2022, an estimated $290K.
AIA Group first reported a position in Ultragenyx Pharmaceutical in Q1 2022 and held it in 1 quarter.
AIA Group's Ultragenyx Pharmaceutical position peaked at $290K in Q1 2022.
223 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2022.

Based on AIA Group's 13F filing for Q2 2022, filed 11 Aug 2022.